Rezolute to Participate in Upcoming Investor Conferences
Rezolute (NASDAQ: RZLT), a late-stage rare disease company specializing in treatments for hypoglycemia caused by hyperinsulinism, has announced its participation in four upcoming investor conferences in May and June 2025. The company's management will attend:
- The Citizens JMP Life Sciences Conference (May 7-8)
- H.C. Wainwright BioConnect Investor Conference (May 20)
- Craig-Hallum Institutional Investor Conference (May 28)
- Jefferies Global Healthcare Conference (June 3-5)
Management will be available for one-on-one meetings with investors during these conferences. Interested investors should contact their respective conference representatives to schedule meetings.
Rezolute (NASDAQ: RZLT), un'azienda in fase avanzata specializzata in malattie rare e nello sviluppo di trattamenti per l'ipoglicemia causata da iperinsulinismo, ha annunciato la sua partecipazione a quattro conferenze per investitori previste per maggio e giugno 2025. Il management dell'azienda sarà presente a:
- The Citizens JMP Life Sciences Conference (7-8 maggio)
- H.C. Wainwright BioConnect Investor Conference (20 maggio)
- Craig-Hallum Institutional Investor Conference (28 maggio)
- Jefferies Global Healthcare Conference (3-5 giugno)
Il management sarà disponibile per incontri individuali con gli investitori durante queste conferenze. Gli investitori interessati sono invitati a contattare i rispettivi rappresentanti delle conferenze per fissare appuntamenti.
Rezolute (NASDAQ: RZLT), una empresa en etapa avanzada especializada en enfermedades raras y tratamientos para la hipoglucemia causada por hiperinsulinismo, ha anunciado su participación en cuatro conferencias para inversores que se realizarán en mayo y junio de 2025. La dirección de la empresa asistirá a:
- The Citizens JMP Life Sciences Conference (7-8 de mayo)
- H.C. Wainwright BioConnect Investor Conference (20 de mayo)
- Craig-Hallum Institutional Investor Conference (28 de mayo)
- Jefferies Global Healthcare Conference (3-5 de junio)
La dirección estará disponible para reuniones individuales con inversores durante estas conferencias. Los inversores interesados deben contactar a los representantes de cada conferencia para programar sus reuniones.
Rezolute (NASDAQ: RZLT)는 고인슐린혈증으로 인한 저혈당 치료에 특화된 후기 단계 희귀질환 전문 기업으로, 2025년 5월과 6월에 열리는 네 차례의 투자자 컨퍼런스에 참여할 예정임을 발표했습니다. 회사 경영진은 다음 행사에 참석할 예정입니다:
- The Citizens JMP Life Sciences Conference (5월 7-8일)
- H.C. Wainwright BioConnect Investor Conference (5월 20일)
- Craig-Hallum Institutional Investor Conference (5월 28일)
- Jefferies Global Healthcare Conference (6월 3-5일)
경영진은 이 컨퍼런스 기간 동안 투자자들과 1:1 미팅을 진행할 예정입니다. 관심 있는 투자자는 각 컨퍼런스 담당자에게 연락하여 미팅 일정을 잡으시기 바랍니다.
Rezolute (NASDAQ : RZLT), une entreprise en phase avancée spécialisée dans les maladies rares et les traitements de l'hypoglycémie causée par l'hyperinsulinisme, a annoncé sa participation à quatre conférences investisseurs prévues en mai et juin 2025. La direction de la société assistera aux événements suivants :
- The Citizens JMP Life Sciences Conference (7-8 mai)
- H.C. Wainwright BioConnect Investor Conference (20 mai)
- Craig-Hallum Institutional Investor Conference (28 mai)
- Jefferies Global Healthcare Conference (3-5 juin)
La direction sera disponible pour des réunions individuelles avec les investisseurs lors de ces conférences. Les investisseurs intéressés sont invités à contacter les représentants des conférences pour organiser des rendez-vous.
Rezolute (NASDAQ: RZLT), ein Unternehmen in der Spätphase, das sich auf seltene Krankheiten und die Behandlung von Hypoglykämie durch Hyperinsulinismus spezialisiert hat, hat seine Teilnahme an vier bevorstehenden Investorenkonferenzen im Mai und Juni 2025 angekündigt. Das Management des Unternehmens wird an folgenden Veranstaltungen teilnehmen:
- The Citizens JMP Life Sciences Conference (7.-8. Mai)
- H.C. Wainwright BioConnect Investor Conference (20. Mai)
- Craig-Hallum Institutional Investor Conference (28. Mai)
- Jefferies Global Healthcare Conference (3.-5. Juni)
Das Management steht für Einzelgespräche mit Investoren während dieser Konferenzen zur Verfügung. Interessierte Investoren sollten sich an die jeweiligen Konferenzvertreter wenden, um Termine zu vereinbaren.
- None.
- None.
REDWOOD CITY, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism, today announced that management will participate in the following investor conferences:
Event: The Citizens JMP Life Sciences Conference
Date: May 7-8, 2025
Event: H.C. Wainwright BioConnect Investor Conference
Date: May 20, 2025
Event: Craig-Hallum Institutional Investor Conference
Date: May 28, 2025
Event: Jefferies Global Healthcare Conference
Date: June 3-5, 2025
Management will be participating in one-on-one investor meetings throughout the conferences. Investors interested in scheduling a meeting with the Rezolute management team should contact their JMP, H.C. Wainwright, Craig-Hallum, and Jefferies representatives.
About Rezolute, Inc.
Rezolute is a late-stage rare disease company focused on significantly improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (“HI”). The Company’s antibody therapy, ersodetug, is designed to treat all forms of HI and has shown substantial benefit in clinical trials and real-world use for the treatment of congenital HI and tumor HI. For more information, visit www.rezolutebio.com.
Contact:
Rezolute, Inc.
Christen Baglaneas
cbaglaneas@rezolutebio.com
508-272-6717
Media
Sarah Lima
Sarah@GalvinPR.com
(774) 766-0200
FAQ
What investor conferences will Rezolute (RZLT) attend in May-June 2025?
What is Rezolute's (RZLT) main business focus?
How can investors meet with Rezolute's management at these conferences?
What stock exchange is Rezolute (RZLT) listed on?
